We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+21.1%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow
% of AUM
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Avg Time Held
0.7
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| 3 | Miscellaneous | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Becton Dickinson
BDX
$52.8B
| $105M | 3.67% |
398,050
+110,050
| +38% | +$27.9M |
2023 Q1
1 quarter
|
|
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $95.9M | 3.35% |
442,200
+38,400
| +10% | +$8.23M |
2022 Q2
4 quarters
|
|
3
Jazz Pharmaceuticals
JAZZ
$13.9B
| $87.1M | 3.04% |
702,778
+24,878
| +4% | +$3.35M |
2022 Q2
4 quarters
|
|
|
4
GE HealthCare
GEHC
$31.8B
| $84.9M | 2.97% |
+1,045,400
| New | +$83.4M |
2023 Q2
0 quarters
|
|
5
Tenet Healthcare
THC
$22.2B
| $80.6M | 2.82% |
990,500
-481,500
| -33% | -$34.3M |
2022 Q4
2 quarters
|
|
6
argenx
ARGX
$53.2B
| $71.8M | 2.51% |
184,300
-96,400
| -34% | -$37.9M |
2022 Q1
5 quarters
|
|
7
IDEAYA Biosciences
IDYA
$3.27B
| $70.2M | 2.45% |
2,985,700
-687,700
| -19% | -$14.1M |
2021 Q1
9 quarters
|
|
|
8
Surgery Partners
SGRY
$1.93B
| $70M | 2.44% |
1,555,000
-1,800,900
| -54% | -$68.7M |
2022 Q3
3 quarters
|
|
|
9
AbbVie
ABBV
$501B
| $69.8M | 2.44% |
+518,400
| New | +$76M |
2023 Q2
0 quarters
|
|
10
Arvinas
ARVN
$468M
| $68.8M | 2.4% |
2,773,189
-1,500,711
| -35% | -$38.6M |
2020 Q2
12 quarters
|
|
11
Zentalis Pharmaceuticals
ZNTL
$212M
| $65.8M | 2.3% |
2,334,000
-595,300
| -20% | -$14.3M |
2020 Q2
12 quarters
|
|
12
Neurocrine Biosciences
NBIX
$13.9B
| $62.7M | 2.19% |
665,316
-150,384
| -18% | -$14.7M |
2020 Q4
10 quarters
|
|
|
13
Eli Lilly
LLY
$1.12T
| $62.4M | 2.18% |
+133,000
| New | +$55.8M |
2023 Q2
0 quarters
|
|
14
Syndax Pharmaceuticals
SNDX
$1.22B
| $60.1M | 2.1% |
2,872,000
-993,300
| -26% | -$20.7M |
2020 Q2
12 quarters
|
|
15
Universal Health Services
UHS
$11B
| $58.4M | 2.04% |
370,100
-299,900
| -45% | -$41.8M |
2022 Q4
2 quarters
|
|
16
Bio-Rad Laboratories Class A
BIO
$9.75B
| $57.9M | 2.02% |
152,600
-68,900
| -31% | -$28M |
2022 Q3
3 quarters
|
|
17
Cencora
COR
$65.2B
| $57.7M | 2.02% |
300,000
+173,400
| +137% | +$30M |
2023 Q1
1 quarter
|
|
18
Pacific Biosciences
PACB
$609M
| $57.7M | 2.01% |
4,337,400
+524,800
| +14% | +$6.38M |
2023 Q1
1 quarter
|
|
19
Legend Biotech
LEGN
$3.85B
| $55.1M | 1.93% |
798,900
-321,600
| -29% | -$21M |
2022 Q4
2 quarters
|
|
20
Biogen
BIIB
$34.8B
| $49.6M | 1.73% |
174,000
+45,200
| +35% | +$13.5M |
2023 Q1
1 quarter
|
|
|
21
DELISTED
Akero Therapeutics
AKRO
| $47.9M | 1.67% |
1,025,000
-1,422,000
| -58% | -$65.2M |
2022 Q3
3 quarters
|
|
22
DELISTED
CureVac
CVAC
| $44.8M | 1.56% |
4,300,000
+750,000
| +21% | +$6.71M |
2023 Q1
1 quarter
|
|
23
Acadia Healthcare
ACHC
$2.89B
| $43.8M | 1.53% |
550,000
-615,300
| -53% | -$44.5M |
2022 Q2
4 quarters
|
|
24
Vaxcyte
PCVX
$10.3B
| $43.7M | 1.53% |
875,000
+365,000
| +72% | +$17.3M |
2022 Q3
3 quarters
|
|
25
McKesson
MCK
$116B
| $43.2M | 1.51% |
+101,200
| New | +$38.9M |
2023 Q2
0 quarters
|
|
Similar funds
ANB
CWM
RIP
TAM
B
PWS
LWP
TAA
Avidity Partners Management's Q2 2023 Portfolio in Review
As of Q2 2023, Avidity Partners Management held 113 positions worth $2.86B, down 5% from $3.01B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Avidity Partners Management withdrew a net $428M in Q2 2023, closing 20 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $63.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Miscellaneous.
Against the trend, Avidity Partners Management opened a new position in GE HealthCare worth $84.9M.
- Avidity Partners Management's largest Q2 2023 buy was GE HealthCare: 1,045,400 shares worth $84.9M.
- Avidity Partners Management added most to Cencora in Q2 2023, an estimated $30M increase.
- Avidity Partners Management's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $72.7M.
- Avidity Partners Management fully exited Merck in Q2 2023, selling an estimated $63.8M.
- Avidity Partners Management's ten largest holdings make up 28% of its $2.86B portfolio in Q2 2023.
- Avidity Partners Management opened 30 new positions and closed 20 in Q2 2023.
- Avidity Partners Management's portfolio value fell 5% quarter-over-quarter to $2.86B.
Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.